Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The new screenshot shows only minor layout and formatting updates on the Study Details page, with no substantive changes to eligibility criteria, endpoints, or the list of study locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-03T19:00:14.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    35 days ago
    Change Detected
    Summary
    Core content updated to reflect funding-related operational notices and new version v3.2.0; previous v3.1.0 version removed.
    Difference
    0.9%
    Check dated 2025-10-06T04:27:06.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    Changed the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.
    Difference
    0.0%
    Check dated 2025-09-29T00:59:18.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    Updated version from v3.0.1 to v3.0.2; removed the 'Back to Top' element. Overall, the substantive content remains the same aside from the version update.
    Difference
    0.1%
    Check dated 2025-09-14T18:46:31.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-09-07T13:07:58.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of new facility names and locations, as well as updated drug information for tepotinib and osimertinib. Notably, the page has removed some previous location details and drug information, indicating a refinement in the content presented.
    Difference
    10%
    Check dated 2025-08-31T04:28:58.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.